Shots:
- AlzeCure Pharma has entered into an out-licensing & collaboration agreement with QuantumCell for global rights to AlzeCure’s Alzheimer’s platform NeuroRestore, incl. ACD856
- AlzeCure will receive $12M upfront, incl. a $5M investment, & is eligible for development & commercial milestones exceeding $2.2B (excl. royalties), plus tiered single to low double-digit royalties
- NeuroRestore ACD856 is a small-molecule Trk-PAM that enhances NGF/TrkA and BDNF/TrkB signaling to improve cognition & has demonstrated neuroprotective, anti-inflammatory, and disease-modifying effects in preclinical studies
Ref: AlzeCure | Image: AlzeCure & QuantumCell | Press Release
Related News: Insilico Medicine Collaborates with Takeda to Advance AI Drug Discovery
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
